Humacyte Inc
NASDAQ:HUMA

Watchlist Manager
Humacyte Inc Logo
Humacyte Inc
NASDAQ:HUMA
Watchlist
Price: 0.97 USD -4.9%
Market Cap: 181.7m USD

Net Margin

-2 357%
Current
Improving
by 51 507.2%
vs 3-y average of -53 864.2%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-2 357%
=
Net Income
$-37m
/
Revenue
$1.6m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-2 357%
=
Net Income
$-37m
/
Revenue
$1.6m

Peer Comparison

Country Company Market Cap Net
Margin
US
Humacyte Inc
NASDAQ:HUMA
183.5m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
380.6B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
181.5B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
157.6B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
116.2B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78B USD
Loading...
AU
CSL Ltd
ASX:CSL
85.3B AUD
Loading...
NL
argenx SE
XBRU:ARGX
42.5B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
46.7B USD
Loading...
No Stocks Found

Market Distribution

Lower than 95% of companies in the United States of America
Percentile
5th
Based on 15 072 companies
5th percentile
-2 357%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Humacyte Inc
Glance View

Market Cap
181.7m USD
Industry
Biotechnology

Humacyte, Inc. engages in the manufacture of human acellular matrix products for vascular and non-vascular applications. The company is headquartered in Durham, North Carolina and currently employs 145 full-time employees. The company went IPO on 2020-09-22. The company is developing a portfolio of human acellular vessels (HAVs) with varying diameters and lengths. The HAV cabinet would initially target the vascular repair, reconstruction and replacement market, including vascular trauma; atrioventricular (AV) access for hemodialysis; peripheral arterial disease (PAD); and coronary artery bypass grafting (CABG). The firm has developed a paradigm for manufacturing human tissues that is intended to mimic key aspects of human physiology. The company is developing and manufacturing acellular tissues to address life- and limb-threatening vascular conditions while focusing on potential future applications for complex tissue and organ diseases. The company is also engaged in developing its HAVs for pediatric heart surgery and the delivery of cellular therapies, including pancreatic islet cell transplantation to treat Type 1 diabetes.

HUMA Intrinsic Value
Not Available
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-2 357%
=
Net Income
$-37m
/
Revenue
$1.6m
What is Humacyte Inc's current Net Margin?

The current Net Margin for Humacyte Inc is -2 357%, which is above its 3-year median of -53 864.2%.

How has Net Margin changed over time?

Over the last 3 years, Humacyte Inc’s Net Margin has decreased from 1 974.1% to -2 357%. During this period, it reached a low of -295 600% on Jun 30, 2023 and a high of 1 974.1% on Sep 30, 2022.

Back to Top